Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/47974
Campo DC Valoridioma
dc.contributor.authorBoronat, Mauroen_US
dc.contributor.authorMarrero, Duniaen_US
dc.contributor.authorLopez Placencia, Yaizaen_US
dc.contributor.authorNovoa Medina, Yerayen_US
dc.contributor.authorGarcía-Delgado, Yaizaen_US
dc.contributor.authorNovoa Mogollón, Franciscoen_US
dc.date.accessioned2018-11-23T17:57:24Z-
dc.date.available2018-11-23T17:57:24Z-
dc.date.issued2012en_US
dc.identifier.issn0804-4643en_US
dc.identifier.urihttp://hdl.handle.net/10553/47974-
dc.description.abstractGrowth failure is a characteristic manifestation of pediatric Cushing's disease. Catch-up growth is usually incomplete after cure of the disease, and final height is often compromised. Possible mechanisms for this phenomenon include postoperative persistence of GH hyposecretion and absence of retardation of bone maturation in spite of GH deficiency. This report describes the outcome in the case of a boy with Cushing's disease for whom GH replacement therapy was combined with anastrozole, an aromatase inhibitor, in order to delay skeletal maturation and extend the available time for linear growth. The case of a 14 years 4-months-old pubertal male (Tanner stage III) with GH deficiency after successful surgical treatment of Cushing's disease is presented. His height was 147.2 cm (-2.34 SDS), and his midparental target height 171.2 cm (-0.95 SDS). Bone age was 13.5 years and predicted adult height 163.2 cm (-2.2 SDS). Combined treatment was administered for 2.5 years. GH was maintained up to age 18 years. Anastrozole induced a substantial deceleration of bone age. Near-final height at 18 years was 169.5 cm (-1.07 SDS). Puberty progressed normally. Compared with population reference data, bone mineral density before GH plus anastrozole treatment was -4.07 SDS in the lumbar spine and -1.85 SDS in the femoral neck. These measures increased to -1.95 and -0.89 SDSs respectively, at 18 years, when GH was discontinued. Combined treatment with GH and aromatase inhibitors could be a therapeutic alternative to improve the stature of pubertal boys with Cushing's disease and postsurgical GH deficiency.en_US
dc.languageengen_US
dc.relation.ispartofEuropean Journal of Endocrinologyen_US
dc.sourceEuropean Journal of Endocrinology[ISSN 0804-4643],v. 166, p. 1101-1105 (Junio 2012)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320502 Endocrinologíaen_US
dc.subject.otherAromatase Inhibitor Letrozoleen_US
dc.subject.otherPredicted Adult Heighten_US
dc.subject.otherBone-Mineral Densityen_US
dc.subject.otherGrowth-Hormoneen_US
dc.subject.otherConstitutional Delayen_US
dc.subject.otherFinal Heighten_US
dc.subject.otherAdolescentsen_US
dc.subject.otherChildrenen_US
dc.subject.otherSexen_US
dc.subject.otherSuppressionen_US
dc.titleCombined treatment with GH and anastrozole in a pubertal boy with Cushing's disease and postsurgical GH deficiencyen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1530/EJE-12-0036en_US
dc.identifier.scopus84862743510-
dc.identifier.isi000304541100017-
dc.contributor.authorscopusid7003952293-
dc.contributor.authorscopusid54080032500-
dc.contributor.authorscopusid6505745223-
dc.contributor.authorscopusid33568100400-
dc.contributor.authorscopusid14050304100-
dc.contributor.authorscopusid12786120600-
dc.description.lastpage1105en_US
dc.description.firstpage1101en_US
dc.relation.volume166en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid673494-
dc.contributor.daisngid9506369-
dc.contributor.daisngid6141456-
dc.contributor.daisngid6056654-
dc.contributor.daisngid6426646-
dc.contributor.daisngid556390-
dc.description.numberofpages5en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Boronat, M-
dc.contributor.wosstandardWOS:Marrero, D-
dc.contributor.wosstandardWOS:Lopez-Plasencia, Y-
dc.contributor.wosstandardWOS:Novoa, Y-
dc.contributor.wosstandardWOS:Garcia-Delgado, Y-
dc.contributor.wosstandardWOS:Novoa, FJ-
dc.date.coverdateJunio 2012en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,451-
dc.description.jcr3,136-
dc.description.sjrqQ1-
dc.description.jcrqQ2-
dc.description.scieSCIE-
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.orcid0000-0001-8535-8543-
crisitem.author.orcid0000-0003-3629-8120-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameBoronat Cortés, Mauro-
crisitem.author.fullNameLopez Plasencia,Yaiza-
crisitem.author.fullNameNovoa Medina,Yeray-
crisitem.author.fullNameNovoa Mogollón,Francisco-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

3
actualizado el 24-mar-2024

Citas de WEB OF SCIENCETM
Citations

2
actualizado el 25-feb-2024

Visitas

64
actualizado el 28-may-2023

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.